Identity and synonyms
Topical cosmetics, free GHK and copper complexes require distinct formulation records.
Synonyms: Copper tripeptide-1 · Copper-GHK
Peptide or peptide-related · Copper–peptide complex
Detailed molecular class: Metal–peptide complex
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Copper-binding peptide studied in extracellular-matrix and wound biology.
Evidence and critical reading
Reported scientific and empirical uses
Recovery and connective tissue · Skin, hair and cosmetics
Handbooks group topical cosmetics, hair, wound healing and systemic injection together. Each use needs separate treatment. A collagen change in cultured cells is a biological observation rather than demonstrated patient improvement.
Human evidence
Topical research does not validate systemic injection or whole-body rejuvenation. Registry entries require separate source-integrity verification and are not clinical results.
Preclinical evidence
Cellular matrix effects are hypothesis-generating, not clinical rejuvenation endpoints.
Critical reading and limitations
Verified studies include cultured human fibroblasts and rat wounds. These must not be counted as human administration trials. Handbooks disagree on quantities and duration; that variability is displayed without averaging. A human trial supporting the specific described injection cycles was not verified.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
1–2 mg · Total daily amount
- Frequency
- Daily
- Duration
- 10–21 days
- Route
- Subcutaneous; source also mentions IM without a separate regimen.
- Context
- Cosmetic/repair claims.
- Presentation
- Not stated on selected page.
- Interpretation
- Does not validate efficacy or safety of this regimen; attributed to the handbook.
manual01 · Page 59 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by 2.pdf
1–4 mg · Total daily amount
- Frequency
- Source says 1–2 times daily without clarifying division of total.
- Duration
- 8–12 weeks
- Route
- Subcutaneous
- Context
- Systemic repair according to source.
- Presentation
- Not stated on selected page.
- Interpretation
- Do not interpret the daily quantity as the amount for each administration. Duration differs from the Handbook.
manual07 · Page 23 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by 4.pdf
1–2 mg · Amount per session
- Frequency
- 3–5 times weekly as reported by source
- Duration
- 4–8-week cycle with 4-week break, as reported by source
- Route
- Subcutaneous or intramuscular as reported by source
- Context
- Volume 4 tissue-repair and cosmetic claims.
- Presentation
- Interpretation
- The manual acknowledges less human research for injection. FDA notes limited human safety data; this exact regimen and claimed synergies were not clinically validated in this review.
manual05 · Page 8 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Injectable safety data are limited; FDA flags immunogenicity/impurity concerns. Copper-related clinical exclusions require product-specific assessment, not invented contraindications.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID1522753 · Cell experiment
Cultured human fibroblasts.
Cell-culture exposure.
Modulation of glycosaminoglycan synthesis.
“Human” describes cell origin, not treated patients.
PMID10383745 · Animal experiment
Experimental rat wounds.
Wound chambers; experimental intervention.
Changes in matrix-related expression/activity.
Not equivalent to systemic human dosing.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
GHK-Cu · 2 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07706361 · Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy AdultsRegistry status: Not yet recruitingLast update posted: July 15, 2026Query verification: October 16, 2026
Source issues and references
Daily amount beside multiple frequency: do not multiply automatically or interpret total as per-administration quantity. · manual07 · Page 23
Calling a synergy “documented” does not itself supply a clinical combination trial. · manual05 · Page 8
Registry record NCT07437586 is held for independent source-integrity verification because it shares a sponsor with records that explicitly describe mock, fictional or example studies. This association does not prove this record false; it is not accepted as authenticated clinical evidence here. · NCT07437586
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID10383745
October 16, 2026
- PMID1522753
October 16, 2026
- R06
- manual01
Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
James B. LaValle; Gordon Crozier; Joseph P. Cleaver; Andrew Heyman
October 16, 2026
Bibliographic attribution only. The supplied handbook is a secondary empirical practice source, not clinical verification. Private source files and supplier/download destinations are not provided here.
- manual05
4.pdf
October 16, 2026
- manual07
2.pdf
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026
- NCT07437586
ClinicalTrials.gov NCT07437586 — source-integrity review hold
October 18, 2026